Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 1, 2013, Pages

  Steingart, Karen R ^a   Sohn, Hojoon ^b   Schiller, Ian ^c   Kloda, Lorie A ^b   Boehme, Catharina C ^d   Pai, Madhukar ^b   Dendukuri, Nandini ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^d FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ATYPICAL MYCOBACTERIOSIS; ATYPICAL MYCOBACTERIUM; BACTERIUM CULTURE; BACTERIUM IDENTIFICATION; COMORBIDITY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERMETHOD COMPARISON; LOW INCOME COUNTRY; LUNG TUBERCULOSIS; META ANALYSIS; MICROSCOPY; MIDDLE INCOME COUNTRY; MULTICENTER STUDY (TOPIC); MULTIDRUG RESISTANT TUBERCULOSIS; PATIENT IDENTIFICATION; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIVITY AND SPECIFICITY; SPUTUM SMEAR; SYSTEMATIC REVIEW; ADULT; DNA SEQUENCE; DRUG EFFECT; GENETICS; ISOLATION AND PURIFICATION; METHODOLOGY; MYCOBACTERIUM TUBERCULOSIS; POLYMERASE CHAIN REACTION;

ADULT; ANTIBIOTICS, ANTITUBERCULAR; DRUG RESISTANCE, BACTERIAL; HUMANS; MYCOBACTERIUM TUBERCULOSIS; POLYMERASE CHAIN REACTION; RIFAMPIN; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, DNA; TUBERCULOSIS, PULMONARY;

MLCS; MLOWN;

EID: 84874887247     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD009593.pub2     Document Type: Review

References (115)

1. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, et al.Rapid molecular detection of tuberculosis and rifampin resistance. New England Journal of Medicine 2010;363:1005-15.
2. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, et al.Rapid molecular detection of tuberculosis and rifampin resistance. New England Journal of Medicine 2010;363:1005-15.
3. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, et al.Rapid molecular detection of tuberculosis and rifampin resistance. New England Journal of Medicine 2010;363:1005-15.
4. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, et al.Rapid molecular detection of tuberculosis and rifampin resistance. New England Journal of Medicine 2010;363:1005-15.
5. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, et al.Rapid molecular detection of tuberculosis and rifampin resistance. New England Journal of Medicine 2010;363:1005-15.
6. Boehme CC, Nicol MP, Nabeta P, Michael JS, Gotuzzo E, Tahirli R, et al.Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 2011;377(9776):1495-505.
7. Boehme CC, Nicol MP, Nabeta P, Michael JS, Gotuzzo E, Tahirli R, et al.Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 2011;377(9776):1495-505.
8. Boehme CC, Nicol MP, Nabeta P, Michael JS, Gotuzzo E, Tahirli R, et al.Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 2011;377(9776):1495-505.
9. Boehme CC, Nicol MP, Nabeta P, Michael JS, Gotuzzo E, Tahirli R, et al.Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 2011;377(9776):1495-505.
10. Boehme CC, Nicol MP, Nabeta P, Michael JS, Gotuzzo E, Tahirli R, et al.Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 2011;377(9776):1495-505.
11. Boehme CC, Nicol MP, Nabeta P, Michael JS, Gotuzzo E, Tahirli R, et al.Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 2011;377(9776):1495-505.
12. Bowles EC, Freyee B, van Ingen J, Mulder B, Boeree M J, van Soolingen D. Xpert MTB/RIF®, a novel automated polymerase chain reaction-based tool for the diagnosis of tuberculosis. International Journal of Tuberculosis and Lung Disease 2011;15:988-9.
13. Ciftci IH, Aslan MH, Asik G. [Evaluation of Xpert MTB/RIF results for the detection of Mycobacterium tuberculosis in clinical samples]. Mikrobiyoloji bulteni 2011;45(1):43-7.
14. Friedrich SO, Venter A, Kayigire XA, Dawson R, Donald PR, Diacon AH. Suitability of Xpert MTB/RIF and genotype MTBDRplus for patient selection for a tuberculosis clinical trial. Journal of Clinical Microbiology 2011;49(8):2827-31.
15. Hanif SN, Eldeen HS, Ahmad S, Mokaddas E. GeneXpert MTB/RIF for rapid detection of Mycobacterium tuberculosis in pulmonary and extra-pulmonary samples. International Journal of Tuberculosis and Lung Disease 2011;15(9):1274-5.
16. Helb D, Jones M, Story E, Boehme C, Wallace E, Ho K, et al.Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. Journal of Clinical Microbiology 2010;48(1):229-37.
17. Ioannidis P, Papaventsis D, Karabela S, Nikolaou S, Panagi M, Raftopoulou E, et al.Cepheid GeneXpert MTB/RIF assay for Mycobacterium tuberculosis detection and rifampin resistance identification in patients with substantial clinical indications of tuberculosis and smear-negative microscopy results. Journal of Clinical Microbiology 2011;49(8):3068-70.
18. Lawn SD, Brooks SV, Kranzer K, Nicol MP, Whitelaw A, Vogt M, et al.Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study. PLoS Medicine 2011;8(7):e1001067.
19. Malbruny B, Le Marrec G, Courageux K, Leclercq R, Cattoir V. Rapid and efficient detection of Mycobacterium tuberculosis in respiratory and non-respiratory samples. International Journal of Tuberculosis and Lung Disease 2011;15(4):553-5.
20. Marlowe EM, Novak-Weekley SM, Cumpio J, Sharp SE, Momeny MA, Babst A, et al.Evaluation of the Cepheid Xpert MTB/RIF assay for direct detection of Mycobacterium tuberculosis complex in respiratory specimens. Journal of Clinical Microbiology 2011;49(4):1621-3.
21. Miller MB, Popowitch EB, Backlund MG, Ager EP. Performance of Xpert MTB/RIF RUO Assay and IS6110 Real-Time PCR for Mycobacterium tuberculosis detection in clinical samples. Journal of Clinical Microbiology 2011;49(10):3458-62.
22. Moure R, Munoz L, Torres M, Santin M, Martin R, Alcaide, F. Rapid detection of Mycobacterium tuberculosis complex and rifampin resistance in smear-negative clinical samples by use of an integrated real-time PCR method. Journal of Clinical Microbiology 2011;49(3):1137-9.
23. Rachow A, Zumla A, Heinrich N, Rojas-Ponce G, Mtafya B, Reither K, et al.Rapid and accurate detection of Mycobacterium tuberculosis in sputum samples by Cepheid Xpert MTB/RIF assay--a clinical validation study. PLoS One 2011;6(6):e20458.
24. Scott LE, McCarthy K, Gous N, Nduna M, Van Rie A, Sanne I, et al.Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study. PLoS Medicine 2011;8(7):e1001061.
25. Teo J, Jureen R, Chiang D, Chan D, Lin R. Comparison of two nucleic acid amplification assays, the Xpert MTB/RIF and the amplified Mycobacterium tuberculosis Direct assay, for the detection of Mycobacterium tuberculosis in respiratory and non-respiratory specimens. Journal of Clinical Microbiology 2011;49(10):3659-62.
26. Theron G, Peter J, van Zyl-Smit R, Mishra H, Streicher E, Murray S, et al.Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting. American Journal of Respiratory Critical Care Medicine 2011;184(1):132-40.
27. Zeka AN, Tasbakan S, Cavusoglu C. Evaluation of the GeneXpert MTB/RIF assay for the rapid diagnosis of tuberculosis and detection of RIF-resistance in pulmonary and extrapulmonary specimens. Journal of Clinical Micobiology 2011;49(12):4138-41.
28. Armand S, Vanhuls P, Delcroix G, Courcol R, Lemaitre N. Comparison of the Xpert MTB/RIF test with an IS6110-TaqMan real-time PCR assay for direct detection of Mycobacterium tuberculosis in respiratory and nonrespiratory specimens. Journal of Clinical Microbiology 2011;49(5):1772-6.
29. Blakemore R, Nabeta P, Davidow A L, Vadwai V, Tahirli R, Munsamy V, et al.A multi-site assessment of the quantitative capabilities of the Xpert(R) MTB/RIF assay. American Journal of Respiratory Critical Care Medicine 2011;184(9):1076-84.
30. Causse M, Ruiz P, Gutierrez-Aroca JB, Casal M. Comparison of two molecular methods for rapid diagnosis of extrapulmonary tuberculosis. Journal of Clinical Microbiology 2011;49(8):3065-7.
31. Friedrich SO, von Groote-Bidlingmaier F, Diacon AH. Xpert MTB/RIF assay for the diagnosis of pleural tuberculosis. Journal of Clinical Microbiology 2011;49(12):4341-2.
32. Hillemann D, Rusch-Gerdes S, Boehme C, Richter E. Rapid molecular detection of extrapulmonary tuberculosis by the automated GeneXpert MTB/RIF system. Journal of Clinical Microbiology 2011;49(4):1202-5.
33. Lawn SD, Nicol MP. Xpert® MTB/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance. Future Microbiology 2011;6(9):1067-82.
34. Ligthelm LJ, Nicol MP, Hoek KG, Jacobson R, van Helden PD, Marais BJ, et al.Xpert MTB/RIF for rapid diagnosis of tuberculous lymphadenitis from fine-needle-aspiration biopsy specimens. Journal of Clinical Microbiology 2011;49(11):3967-70.
35. Nicol MP, Workman L, Isaacs W, Munro J, Black F, Eley B, et al.Accuracy of the Xpert MTB/RIF test for the diagnosis of pulmonary tuberculosis in children admitted to hospital in Cape Town, South Africa: a descriptive study. Lancet Infectious Diseases 2011;11(11):819-24.
36. Vadwai V, Boehme C, Nabeta P, Shetty A, Alland D, Rodrigues C. Xpert MTB/RIF: a new pillar in diagnosis of extrapulmonary tuberculosis?. Journal of Clinical Microbiology 2011;49(7):2540-5.
37. Van Rie A, Page-Shipp L, Scott L, Sanne I, Stevens W. Xpert(®) MTB/RIF for point-of-care diagnosis of TB in high-HIV burden, resource-limited countries: hype or hope?. Expert Review of Molecular Diagnostics 2010;10(7):937-46.
38. Multicentre randomised control trial of point-of-treatment (Clinic-based) Xpert MTB/RIF assay. Ongoing study 7 July 2011.
39. Evaluation of Xpert MTB/RIF assay for the rapid identification of TB and TB rifampin resistance in HIV-infected and HIV-uninfected pulmonary tuberculosis suspects. Ongoing study 24 April 2012.
40. A randomised control trial of sputum induction, and new and emerging technologies in a high HIV prevalence primary care setting. Ongoing study August 2009.
41. Abimbola TO, Marston BJ, Date AA, Blandford JM, Sangrujee N, Wiktor SZ. Cost-effectiveness of tuberculosis diagnostic strategies to reduce early mortality among persons with advanced HIV infection initiating antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes 2012;60(1):e1-7.
42. Andrews JR, Lawn SD, Rusu C, Wood R, Noubary F, Bender MA, et al.The cost-effectiveness of routine tuberculosis screening with Xpert MTB/RIF prior to initiation of antiretroviral therapy: a model-based analysis. AIDS 2012;26(8):987-95.
43. Banada PP, Sivasubramani SK, Blakemore R, Boehme C, Perkins MD, Fennelly K, et al.Containment of bioaerosol infection risk by the Xpert MTB/RIF assay and its applicability to point-of-care settings. Journal of Clinical Microbiology 2010;48(10):3551-7.
44. Blakemore R, Story E, Helb D, Kop J, Banada P, Owens MR, et al.Evaluation of the analytical performance of the Xpert MTB/RIF assay. Journal of Clinical Microbiology 2010;48(7):2495-501.
45. Boehme CC, Nabeta P, Henostroza G, Raqib R, Rahim Z, Gerhardt M, et al.Operational feasibility of using loop-mediated isothermal amplification for diagnosis of pulmonary tuberculosis in microscopy centers of developing countries. Journal of Clinical Microbiology 2007;45(6):1936-40.
46. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al.The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Clinical Chemistry 2003;49(1):7-18.
47. Bossuyt PM, Leeflang MM. Chapter 6: Developing Criteria for Including Studies. Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy Version 0.4 [updated September 2008]. The Cochrane Collaboration, 2008.
48. Buzoianu M, Kadane JB. Adjusting for Verification Bias in Diagnostic Test Evaluation: A Bayesian Approach. Statististics in Medicine 2008;27:2453-2473.
49. Centers for Disease Control and Prevention (CDC). Updated guidelines for the use of nucleic acid amplification tests in the diagnosis of tuberculosis. Morbidity and Mortality Weekly Report 2009;58(1):7-10.
50. Cepheid. Brochure: Xpert®MTB/RIF. Two-hour detection of MTB and resistance to rifampicin. http://www.cepheid.com/media/files/eu/brochures/XpertMTB_Broch_R9_EU.pdf. Sunnyvale, Accessed 17 June 2012.
51. Chaisson RE, Nuermberger EL. Confronting multidrug-resistant tuberculosis. New England Journal of Medicine 2012;366(23):2223-4.
52. Chang K, Lu W, Wang J, Zhang K, Jia S, Li F, et al.Rapid and effective diagnosis of tuberculosis and rifampicin resistance with Xpert MTB/RIF assay: a meta-analysis. Journal of Infection 2012;64(6):580-8.
53. Chu H, Chen S, Louis TA. Random Effects Models in a Meta-Analysis of the Accuracy of Two Diagnostic Tests Without a Gold Standard. J Am Stat Association 2009;104:512-23.
54. Dowdy DW, Cattamanchi A, Steingart KR, Pai M. Is scale-up worth it? Challenges in economic analysis of diagnostic tests for tuberculosis. PLoS Medicine 2011; Vol. 8, issue 7:e1001063.
55. Drobniewski F, Nikolayevskyy V, Balabanova Y, Bang D, Papaventsis D. Diagnosis of tuberculosis and drug resistance: what can new tools bring us?. International Journal of Tuberculosis and Lung Disease 2012;16(7):860-70.
56. Flores LL, Pai M, Colford JM Jr, Riley LW. In-house nucleic acid amplification tests for the detection of Mycobacterium tuberculosis in sputum specimens: meta-analysis and meta-regression. BMC Microbiology 2005;5:55.
57. Getahun H, Harrington M, O'Brien R, Nunn P. Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changes. Lancet 2007;369(9578):2042-9.
58. Gopinath K, Singh S. Non-tuberculous mycobacteria in TB-endemic countries: Are we neglecting the danger?. PLoS Neglected Tropical Diseases 2010;4(4):e615.
59. Greco S, Girardi E, Navarra A, Saltini C. Current evidence on diagnostic accuracy of commercially based nucleic acid amplification tests for the diagnosis of pulmonary tuberculosis. Thorax 2006;61(9):783-90.
60. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al.GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64(4):383-94.
61. Hadgu A, Dendukuri N, Hilden J. Evaluation of nucleic acid amplification tests in the absence of a perfect gold-standard test: a review of the statistical and epidemiologic issues. Epidemiology 2005;16(5):604-12.
62. Harries A. How does the diagnosis of tuberculosis in persons infected with HIV differ from diagnosis in persons not infected with HIV?. In: Frieden T editor(s). Toman's tuberculosis: case detection, treatment, and monitoring - questions and answers. WHO/HTM/TB/2004.334. Geneva: World Health Organization, 2004:80-3.
63. Hartmann G, Honikel KO, Knusel F, Nuesch J. The specific inhibition of the DNA-directed RNA synthesis by rifamycin. Biochimica et Biophysica Acta 1967;145(3):843-4.
64. Tuberculosis coalition for technical assistance. International Standards for Tuberculosis Care (ISTC). Second Edition. The Hague: Tuberculosis coalition for technical assistance, 2009.
65. Juni P, Witschi A, Bloch R, Egger M. The hazards of scoring the quality of clinical trials for meta-analysis. Journal of the American Medical Association 1999;282(11):1054-60.
66. Ling DI, Zwerling AA, Pai M. GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis. European Respiratory Journal 2008;32(5):1165-74.
67. Ling DI, Flores LL, Riley LW, Pai M. Commercial nucleic-acid amplification tests for diagnosis of pulmonary tuberculosis in respiratory specimens: meta-analysis and meta-regression. PLoS One 2008;3(2):e1536.
68. Lunn DJ, Thomas A, Best N, Spiegelhalter D. WinBUGS - a Bayesian modelling framework: concepts, structure, and extensibility. Statistics and Computing 2000;10:325-37.
69. Macaskill P, Gatsonis C, Deeks JJ, Harbord RM, Y Takwoingi. Analysing and Presenting Results. In: Deeks JJ, Bossuyt PM, C Gatsonis editor(s). Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy. Version 0.9.0. The Cochrane Collaboration, 2010.
70. Martin A, Portaels F, Palomino JC. Colorimetric redox-indicator methods for the rapid detection of multidrug resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy 2007;59(2):175-83.
71. Martin A, Panaiotov S, Portaels F, Hoffner S, Palomino JC, Angeby K. The nitrate reductase assay for the rapid detection of isoniazid and rifampicin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy 2008;62(1):56-64.
72. Meyer-Rath G, Schnippel K, Long L, MacLeod W, Sanne I, Stevens W, et al.The impact and cost of scaling up GeneXpert MTB/RIF in South Africa. PLoS One 2012; Vol. 7, issue 5:e36966.
73. Miotto P, Bigoni S, Migliori GB, Matteelli A, Cirillo DM. Early tuberculosis treatment monitoring by Xpert® MTB/RIF. European Respiratory Journal 2012;39(5):1269-71.
74. Moore DA, Evans CA, Gilman RH, Caviedes L, Coronel J, Vivar A, et al.Microscopic-observation drug-susceptibility assay for the diagnosis of TB. New England Journal of Medicine 2006;355(15):1539-50.
75. Nahid P, Kim PS, Evans CA, Alland D, Barer M, Diefenbach J, et al.Clinical research and development of tuberculosis diagnostics: moving from silos to synergy. Journal of Infectious Disease 2012;205(Suppl 2):S159-68.
76. Perkins MD, Cunningham J. Facing the crisis: improving the diagnosis of tuberculosis in the HIV era. Journal of Infectious Diseases 2007;196(Suppl 1):S15-27.
77. R Development Core Team. R: A language and environment for statistical computing. Version 2.15.1. Vienna: R Foundation for Statistical Computing, 2008.
78. Rachow A, Clowes P, Saathoff E, Mtafya B, Michael E, Ntinginya EN, et al.Increased and expedited case detection by Xpert MTB/RIF assay in childhood tuberculosis: a prospective cohort study. Clinical Infectious Diseases 2012;54(10):1388-96.
79. Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinderman AH. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. Journal of Clinical Epidemiology 2005;58(10):982-90.
80. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
81. Schnippel K, Meyer-Rath G, Long L, MacLeod W, Sanne I, et al.Scaling up Xpert MTB/RIF technology: the costs of laboratory- vs. clinic-based roll-out in South Africa. Tropical Medicine and International Health 2012;17(9):1142-51.
82. Small PM, Pai M. Tuberculosis diagnosis - time for a game change. New England Journal of Medicine 2011;363(111):1070-1.
83. SPSS Inc. SPSS for Windows. 14.0.1.366. Chicago: SPSS Inc., 2006.
84. Steingart KR, Henry M, Ng V, Hopewell PC, Ramsay A, Cunningham J, et al.Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review. Lancet Infectious Diseases 2006;6(9):570-81.
85. Steingart KR, Ng V, Henry M, Hopewell PC, Ramsay A, Cunningham J, et al.Sputum processing methods to improve the sensitivity of smear microscopy for tuberculosis: a systematic review. Lancet Infectious Diseases 2006;6(10):664-74.
86. Telenti A, Imboden P, Marchesi F, Lowrie D, Cole S, Colston MJ, et al.Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 1993;341(8846):647-50.
87. The Gates Foundation. Public-Private Partnership Announces Immediate 40 Percent Cost Reduction for Rapid TB Test. http://www.gatesfoundation.org/press-releases/Pages/public-private-partnership-40-percent-reduction-TB-test.aspx 6 August 2012.
88. Toman K. How many bacilli are present in a sputum specimen found positive by smear microscopy?. In: Frieden T editor(s). Toman's tuberculosis: case detection, treatment, and monitoring - questions and answers. WHO/HTM/TB/2004.334. Geneva: World Health Organization, 2004:11-13.
89. Tortoli E, Russo C, Piersimoni C, Mazzola E, Dal Monte P, Pascarella M, et al.Clinical validation of Xpert MTB/RIF for the diagnosis of extrapulmonary tuberculosis. European Respiratory Journal 2012;40(2):442-7.
90. Trébucq A, Enarson DA, Chiang CY, Van Deun A, Harries AD, Boillot F, et al.Xpert® MTB/RIF for national tuberculosis programmes in low-income countries: when, where and how?. International Journal of Tuberculosis and Lung Disease 2011;15(12):1567-72.
91. Boyle D, Pai M. UNITAID: Tuberculosis diagnostic technology landscape. Geneva: WHO, 2012.
92. UNITAID. UNITAID approves US$30 million for innovative project to roll out ground-breaking tuberculosis test at reduced cost. http://www.unitaid.eu/resources/news/releases/943-unitaid-approves-us-30-million-for-innovative-project-to-roll-out-ground-breaking-tuberculosis-test-at-reduced-cost 13 June 2012.
93. Van Deun A, Barrera L, Bastian I, Fattorini L, Hoffmann H, Kam KM, et al.Mycobacterium tuberculosis strains with highly discordant rifampin susceptibility test results. Journal of Clinical Microbiology 2009;47(11):3501-6.
94. Vassall A, van Kampen S, Sohn H, Michael JS, John KR, den Boon S, et al.Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a cost-effectiveness analysis. PLoS Medicine 2011; Vol. 8, issue 11:e1001120.
95. Whiting P, Harbord R, Kleijnen J. No role for quality scores in systematic reviews of diagnostic accuracy studies. BMC Medical Research Methodology. 2005;5:19.
96. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al.QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Annals of Internal Medicine 2011;155(8):529-36.
97. World Health Organization. Anti-tuberculosis drug resistance in the world: fourth global report. WHO/HTM/TB/2008.394. Geneva: World Health Organization, 2008.
98. World Health Organization. Global tuberculosis control: WHO report 2011. WHO/HTM/TB/2011.16. Geneva: World Health Organization, 2011.
99. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis- 2011 update. WHO/HTM/TB/2011.6. Geneva: World Health Organization, 2011.
100. World Health Organization. Treatment of tuberculosis: guidelines WHO/HTM/TB/2009.420. 4th Edition. Geneva: World Health Organization, 2010.
101. World Health Organization. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. WHO/HTM/TB/2010.3. Geneva: World Health Organization, 2010.
102. World Health Organization. Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs. WHO/HTM/TB/2008.392. Geneva: World Health Organization, 2008.
103. World Health Organization. Policy framework for implementing new tuberculosis diagnostics. Geneva: World Health Organization, 2011.
104. World Health Organization. Molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis (MDR-TB). Geneva: World Health Organization, 2008.
105. World Health Organization. Noncommercial culture and drug-susceptibility testing methods for screening patients at risk for multidrug-resistant tuberculosis. Geneva: World Health Organization, 2011.
106. World Health Organization. Definition of a new sputum smear-positive TB case. http://www.who.int/tb/laboratory/policy_sputum_smearpositive_tb_case/en/index.html 2007.
107. World Health Organization. Policy statement: automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system. WHO/HTM/TB/2011.4. Geneva: World Health Organization, 2011.
108. World Health Organization. Rapid implementation of the Xpert MTB/RIF diagnostic test. Technical and operational 'How-to'. Practical considerations. WHO/HTM/TB/2011.2. Geneva: World Health Organization, 2011.
109. World Health Organization. Checklist of prerequisites to country implementation of Xpert MTB/RIF and key action points at country level. WHO/HTM/TB/2011.12. Geneva: World Health Organization, 2011.
110. Williamson DA, Roberts SA, Bower JE, Vaughan R, Newton S, Lowe O, et al.Clinical failures associated with rpoB mutations in phenotypically occult multidrug-resistant Mycobacterium tuberculosis. International Journal of Tuberculosis and Lung Disease 2012;16:216-20.
111. World Bank. World Bank List of Economies http://siteresources.worldbank.org/DATASTATISTICS/Resources/CLASS.XL. Washington (District of Columbia): World Bank, 2011.
112. Wright A, Zignol M, Van Deun A, Falzon D, Gerdes SR, Feldman K, et al.Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet 2009;373(9678):1861-73.
113. Rachow A, Clowes P, Saathoff E, Mtafya B, Michael E, Ntinginya EN, et al.Increased and expedited case detection by Xpert MTB/RIF assay in childhood tuberculosis: a prospective cohort study. Clinical Infectious Diseases 2012;54(10):1388-96.
114. Zignol M, van Gemert W, Falzon D, Sismanidis C, Glaziou P, Floyd K, et al.Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007-2010. Bulletin of the World Health Organization 2012;90(2):111-119D.
115. Zumla A, Abubakar I, Raviglione M, Hoelscher M, Ditiu L, McHugh TD, et al.Drug-resistant tuberculosis--current dilemmas, unanswered questions, challenges, and priority needs. Journal of Infectious Diseases 2012;205(Suppl 2):S228-40.